JeffreySWeberMD

Physician

Telehealth Available

Overview of Dr. Weber

Dr. Jeffrey Weber is an oncologist in New York, NY and is affiliated with NYU Langone Hospitals. He received his medical degree from New York University Grossman School of Medicine and has been in practice 37 years. Dr. Weber accepts several types of health insurance, listed below. He is one of 125 doctors at NYU Langone Hospitals who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
160 East 34th Street
9th Floor
New York, NY 10016
Book by Phone212-731-6262

Fax+1 212-263-9201
Is this information wrong?

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1985 - 1988
University of California (San Diego) Medical CenterInternship, Internal Medicine, 1980 - 1981
New York University School of MedicineClass of 1980

Certifications & Licensure

CA State Medical License 1994 - Present
NY State Medical License 1983 - 2023
FL State Medical License 2007 - 2017
MD State Medical License 1985 - 1995
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Phase I/II Study of Dasatinib and Dacarbazine Start of enrollment: 2007 Nov 01
Completed
Phase 1, Phase 2
Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma Start of enrollment: 2009 Jan 23
Completed
Phase 2
Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100 Start of enrollment: 2009 Oct 01
Completed
Phase 1
Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma Start of enrollment: 2010 Aug 13
Active, not recruiting
Phase 1
Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC Start of enrollment: 2011 Oct 11
Terminated
Phase 2
Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma Start of enrollment: 2012 Feb 17
Completed
Phase 1
Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma Start of enrollment: 2012 Jul 27
Active, not recruiting
Phase 1
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma Start of enrollment: 2012 Aug 03
Active, not recruiting
Phase 2
Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts Start of enrollment: 2012 Oct 09
Active, not recruiting
Not Applicable
Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma Start of enrollment: 2014 Jan 07
Active, not recruiting
Phase 1
An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma Start of enrollment: 2014 Sep 29
Terminated
Phase 1, Phase 2
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma Start of enrollment: 2019 Jun 11
Recruiting
Phase 2
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma Start of enrollment: 2019 Oct 28
Active, not recruiting
Phase 3
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma Start of enrollment: 2022 Sep 01
Not yet recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1).
Sophie Postel-Vinay, Vincent K Lam, Willeke Ros, Todd M Bauer, Aaron R Hansen, Daniel C Cho, F Stephen Hodi, Jan H M Schellens, Jennifer K Litton, Sandrine Aspeslagh, ...> ;Journal for Immunotherapy of Cancer. 2023 Mar 1
Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to t...
Jeffrey S Weber, Tayla Poretta, Brian D Stwalley, Leon A Sakkal, Ella X Du, Travis Wang, Yan Chen, Yan Wang, Keith A Betts, Alexander N Shoushtari> ;Cancer Immunology, Immunotherapy. 2023 Apr 1
1 citations
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immu...
Jason Chesney, Karl D Lewis, Harriet Kluger, Omid Hamid, Eric Whitman, Sajeve Thomas, Martin Wermke, Mike Cusnir, Evidio Domingo-Musibay, Giao Q Phan, John M Kirkwood,...> ;Journal for Immunotherapy of Cancer. 2022 Dec 1
Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma.
Nikhil I Khushalani, Melinda Vassallo, Judith D Goldberg, Zeynep Eroglu, Younchul Kim, Biwei Cao, Robert Ferguson, Kelsey R Monson, Tomas Kirchhoff, Carol M Amato, Pau...> ;Journal for Immunotherapy of Cancer. 2022 Nov 1
Nanoparticle-based modulation of CD4T cell effector and helper functions enhances adoptive immunotherapy.
Ariel Isser, Aliyah B Silver, Hawley C Pruitt, Michal Mass, Emma H Elias, Gohta Aihara, Si-Sim Kang, Niklas Bachmann, Ying-Yu Chen, Elissa K Leonard, Joan G Bieler, Wo...> ;Nature Communications. 2022 Oct 14
Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma.
MacLean S Hall, John E Mullinax, Cheryl A Cox, Amy M Hall, Matthew S Beatty, Jamie Blauvelt, Patrick Innamarato, Luz Nagle, Holly Branthoover, Doris Wiener, Benjamin S...> ;Clinical Cancer Research. 2022 Dec 15
Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis f...
Jeffrey S Weber, Tayla Poretta, Brian D Stwalley, Leon A Sakkal, Ella X Du, Travis Wang, Yan Chen, Yan Wang, Keith A Betts, Alexander N Shoushtari> ;Cancer Immunology, Immunotherapy. 2023 Apr 1
Risk and tropism of central nervous system (CNS) metastases in patients with stage II and III cutaneous melanoma.
Paul Johannet, Morgan Simons, Yingzhi Qian, Nadine Azmy, Janice M Mehnert, Jeffrey S Weber, Judy Zhong, Iman Osman> ;The Journal of Steroid Biochemistry and Molecular Biology. 2022 Oct 1
Intratumoral Therapy to Make a "Cold" Tumor "Hot": The Jury Is Still Out.
Salman R Punekar, Jeffrey S Weber> ;Clinical Cancer Research. 2022 Dec 1
7 citations
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).
Jeffrey S Weber, Dirk Schadendorf, Michele Del Vecchio, James Larkin, Victoria Atkinson, Michael Schenker, Jacopo Pigozzo, Helen Gogas, Stéphane Dalle, Nicolas Meyer, ...> ;Journal of Clinical Oncology. 2023 Jan 20
3 citations
Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade.
Paul Johannet, Wenke Liu, David Fenyo, Megan Wind-Rotolo, Michelle Krogsgaard, Janice M Mehnert, Jeffrey S Weber, Judy Zhong, Iman Osman> ;Clinical Cancer Research. 2022 Sep 15
2 citations
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria.
James Larkin, Jeffrey Weber, Michele Del Vecchio, Helen Gogas, Ana M Arance, Stephane Dalle, C Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion-Sileni,...> ;European Journal of Cancer. 2022 Sep 1
Real-World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma.
Wolfram Samlowski, Nicholas J Robert, Liwei Chen, Brad Schenkel, Catherine Davis, Andriy Moshyk, Srividya Kotapati, Tayla Poretta, Jeffrey S Weber> ;Cancer Medicine. 2023 Feb 1
1 citations
Immune checkpoint inhibition in patients with inactive pre-existing neuromuscular autoimmune diseases.
Andrew Snavely, Eduardo J Pérez-Torres, Jeffrey S Weber, Sabina Sandigursky, Sujata P Thawani> ;Journal of the Neurological Sciences. 2022 Jul 15
2 citations
American Association of Clinical Endocrinology Disease State Clinical Review: Evaluation and Management of Immune Checkpoint Inhibitor-Mediated Endocrinopathies: A Pra...
Kevin C J Yuen, Susan L Samson, Irina Bancos, Aidar R Gosmanov, Sina Jasim, Leslie A Fecher, Jeffrey S Weber> ;Endocrine Practice. 2022 Jul 1
2 citations
The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases - A multicenter cohort study.
Carl-Jacob Holmberg, Lars Ny, Tina J Hieken, Matthew S Block, Michael J Carr, Vernon K Sondak, Christoffer Örtenwall, Dimitrios Katsarelias, Florentia Dimitriou, Alexa...> ;European Journal of Cancer. 2022 Jul 1
Significant survival improvements for patients with melanoma brain metastases: can we reach cure in the current era?
Assaf Berger, Kenneth Bernstein, Juan Diego Alzate, Reed Mullen, Joshua S Silverman, Erik P Sulman, Bernadine R Donahue, Anna C Pavlick, Jason Gurewitz, Monica Mureb, ...> ;Journal of Neuro-Oncology. 2022 Jul 1
3 citations
PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence.
Alexander Mm Eggermont, Paolo A Ascierto, Nikhil I Khushalani, Dirk Schadendorf, Genevieve Boland, Jeffrey Weber, Karl D Lewis, Daniel Johnson, Gareth Rivalland, Adnan...> ;Future Oncology. 2022 Mar 1
A genome-wide association study of germline variation and melanoma prognosis.
Vylyny Chat, Sasha Dagayev, Una Moran, Matija Snuderl, Jeffrey Weber, Robert Ferguson, Iman Osman, Tomas Kirchhoff> ;Frontiers in Oncology. 2022 Jan 1
Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont.
Jeffrey Weber, Mario Mandala, Paolo Antonio Ascierto, James Larkin> ;Journal for Immunotherapy of Cancer. 2022 Jan 1
187 citations
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.
Bryan J. Schneider, Jarushka Naidoo, Bianca Santomasso, Christina Lacchetti, Sherry Adkins, Milan J. Anadkat, Michael B. Atkins, Kelly J. Brassil, Jeffrey M. Caterino,...> ;Journal of Clinical Oncology. 2021 Nov 1
33 citations
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline.
Bianca Santomasso, Loretta J. Nastoupil, Sherry Adkins, Christina Lacchetti, Bryan J. Schneider, Milan J. Anadkat, Michael B. Atkins, Kelly J. Brassil, Jeffrey M. Cate...> ;Journal of Clinical Oncology. 2021 Nov 1
7 citations
Deep learning and pathomics analyses reveal cell nuclei as important features for mutation prediction of BRAF-mutated melanomas.
Randie H Kim, Sofia Nomikou, Nicolas Coudray, George Jour, Zarmeena Dawood, Runyu Hong, Eduardo Esteva, Theodore Sakellaropoulos, Douglas Donnelly, Una Moran, Aristide...> ;The Journal of Investigative Dermatology. 2021 Oct 29
5 citations
Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma.
Jeffrey S. Weber, Paolo A. Ascierto, Mark R. Middleton, Delphine Hennicken, Roberto Zoffoli, Anne Pieters, Adenike Amadi, Katrin Kupas, Srividya Kotapati, Andriy Moshy...> ;European Journal of Cancer. 2021 Oct 15
4 citations
Preexisting immune-mediated inflammatory disease is associated with improved survival and increased toxicity in melanoma patients who receive immune checkpoint inhibit...
Nicholas Gulati, Arda Celen, Paul Johannet, Janice M. Mehnert, Jeffrey S. Weber, Michelle Krogsgaard, Iman Osman, Judy Zhong> ;Journal of Clinical Oncology. 2021 Oct 14
Join now to see all

Journal Articles

The Society for Immunotherapy of Cancer Perspective on Regulation of Interleukin-6 Signaling in COVID-19-Related Systemic Inflammatory Response
Steven J O'Day, Walter J Urba, Jeffrey S Weber, Journal For Immunotherapy of Cancer

Lectures

Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition.
2019 ASCO Annual Meeting - 6/1/2019
Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

Opdivo Shows Better Results Than Yervoy in Melanoma PatientsNovember 16th, 2019
Dr. Weber on the Toxicity Profile of Nivolumab Versus Ipilimumab for MelanomaNovember 8th, 2017
Dr. Weber on Nivolumab in the Adjuvant Setting for MelanomaOctober 20th, 2017
Join now to see all

Hospital Affiliations

NYU Langone HospitalsNew York, New York

Insurance Accepted

Aetna Choice POS II
Aetna HMO
AmeriHealth Direct POS
AmeriHealth Direct POS Value Network
Amerihealth HMO
AmeriHealth HMO Value Network
AmeriHealth PPO
AmeriHealth PPO Value Network
AvMed Health Open Access
BCBS Blue Card PPO
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
BCBS New Mexico PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Cofinity PPO
Coventry Carelink Health Plans PPO
Coventry Florida - Employer Group PPO
First Health PPO
GHI PPO
Great West PPO
HealthAmerica HealthAssurance PPO
HIP of New York - Select PPO
Horizon BCBS Direct Access
Horizon BCBS HMO
Horizon BCBS POS
Horizon BCBS PPO
Humana ChoiceCare Network PPO
IBC Keystone HMO / POS
IBC Personal Choice PPO
Lovelace Health Plan PPO
Multiplan PHCS PPO
Multiplan PPO
Oxford Health Freedom
Oxford Health Liberty
Presbyterian Commercial
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
WEA Trust Preferred Provider Plan - Trust Pref
Please verify your coverage with the provider's office directly when scheduling an appointment